Breast Cancer

Overweight and obesity increase the risk of developing several cancers.Once cancer develops, individuals may be at increased risk of recurrenceand poorer survival if they are overweight or obese. A statisticallysignificant association between overweight or obesity and breast cancerrecurrence or survival has been observed in the majority of populationbasedcase series; however, adiposity has been shown to have less of aneffect on prognosis in the clinical trial setting. Weight gain after breastcancer diagnosis may also be associated with decreased prognosis. Newevidence suggests that overweight/obesity vs normal weight may increasethe risk of poor prognosis among resected colon cancer patients and therisk of chemical recurrence in prostate cancer patients. Furthermore, obesecancer patients are at increased risk for developing problems followingsurgery, including wound complication, lymphedema, second cancers,and the chronic diseases affecting obese individuals without cancer suchas cardiovascular disease and diabetes. Mechanisms proposed to explainthe association between obesity and reduced prognosis include adiposetissue-induced increased concentrations of estrogens and testosterone,insulin, bioavailable insulin-like growth factors, leptin, and cytokines.Additional proposed mechanisms include reduced immune functioning,chemotherapy dosing, and differences in diet and physical activityin obese and nonobese patients. There have been no randomized clinicaltrials testing the effect of weight loss on recurrence or survival inoverweight or obese cancer patients, however. In the absence of clinicaltrial data, normal weight, overweight, and obese patients should beadvised to avoid weight gain through the cancer treatment process. Inaddition, weight loss is probably safe, and perhaps helpful, for overweightand obese cancer survivors who are otherwise healthy.

PHOENIX-Between 17.5% and 29.8% of 57 nonmetastatic breast cancer patients had cognitive impairment prior to starting chemotherapy in an ongoing study exploring the effects of chemotherapy on cognitive functioning among breast

SAN ANTONIO-Long-term disease-free survival in node-positive, estrogen-receptor (ER)-positive postmenopausal breast cancer patients is improved when hormonal therapy follows chemotherapy, according to a 10-year analysis of the

Drs. Partridge and Schapira areto be complimented on a conciseand comprehensive reviewof pregnancy before, during, andafter a diagnosis of breast cancer. Aswomen are able and willing to deferpregnancy until later in life, the issuesaddressed in this article will be encounteredwith increasing frequencyin oncology.

Drs. Patridge and Schapira setout to review breast cancerand pregnancy, discuss treatmentoptions for breast cancer duringpregnancy, and summarize the availableevidence regarding safety of pregnancyafter breast cancer. This is asubstantial undertaking. They beginby reviewing the epidemiologic dataindicating an early increase in risk ofbreast cancer development after pregnancyand the likely long-term protectiveeffect of pregnancy on breastcancer risks. The subsequent focus oftheir review is on breast cancer duringpregnancy, a relatively rare occurrence.In a study from California,Smith et al indicated that the frequencyof breast cancer concurrent withpregnancy was 1.3 per 10,000 livesingleton births.[1] The authors notea frequently quoted figure of 1 in 3,000pregnancies.

The relationship between pregnancy and breast cancer is complex,and a paucity of available data further complicates decision-makingfor many women diagnosed with breast cancer during pregnancy ordesiring to become pregnant after such a diagnosis. Treatment of breastcancer during pregnancy requires a multidisciplinary care team andcareful consideration of the risk of the disease and gestational age ofthe fetus, in conjunction with the patient’s preferences. Chemotherapyshould be deferred beyond the first trimester. There is no evidence thatpregnancy in a breast cancer survivor will decrease long-term survival;in fact, studies suggest a potential protective effect of pregnancy afterbreast cancer in terms of the risk of recurrence. However, the availablestudies are limited by substantial potential biases, and concerns remainfor some women and their doctors about the risks of pregnancy afterbreast cancer. This article reviews what is known about the associationbetween pregnancy and breast cancer, discusses treatment options forwomen diagnosed with the disease during pregnancy, and summarizesevidence regarding the safety of pregnancy after breast cancer.

Targeted therapies offer a new approach to breast cancer treatment.Rather than eliminating both malignant and normal cellsnonspecifically, these so-called “rational” therapies exploit second messengerproteins, ligands, and receptors that are known to be upregulatedin neoplastic cells, or are implicated in cancer metastasis. This reviewwill highlight a number of these targets and the mechanisms that havebeen targeted in drug design. We will also describe recently completedand currently ongoing clinical trials investigating targeted therapiesand their potential to augment standard breast cancer therapy.

Recent advances in treatment modalities for breast and prostate cancerhave resulted in an increasing number of patients that are cured orthat, despite residual disease, live long enough to start experiencingcomplications from cancer treatment. Osteoporosis is one such problemthat has been increasingly identified in cancer patients. Hypogonadismand glucocorticoid use are the two major causes of bone loss inthese patients. Osteoporosis is characterized by low bone mass and abnormalbone microarchitecture, which results in an increased risk offractures. Vertebral body and hip fractures commonly result in a drasticchange of quality of life as they can result in disabling chronic pain,loss of mobility, and loss of independence in performing routine dailyactivities, as well as in increased mortality. In patients with prostatecarcinoma, androgen-deprivation therapy by either treatment with agonadotropin-releasing hormone (GnRH) or bilateral orchiectomy resultsin increased bone turnover, significant bone loss, and increasedrisk of fractures. Patients with breast cancer are at increased risk forestrogen deficiency due to age-related menopause, ovarian failure fromsystemic chemotherapy, or from the use of drugs such as aromataseinhibitors and GnRH analogs. Several studies have indicated that theprevalence of fractures is higher in breast and prostate cancer patientscompared to the general population. Therefore, patients at risk for boneloss should have an assessment of their bone mineral density so thatprevention or therapeutic interventions are instituted at an early enoughstage to prevent fractures. This article will address the characteristicsof bone loss observed in breast and prostate cancer patients and potentialtreatments.

The improved survival associated with adding the anti-vascular endothelialgrowth factor (VEGF) monoclonal antibody bevacizumab(Avastin) to chemotherapy for the treatment of patients with metastaticcolorectal cancer demonstrates the importance of targeting collateralcells involved in tumor growth, progression, and metastatic spread.Based on the Gompertzian model of tumor growth, adding anti-VEGFagents to standard chemotherapy may be especially effective in earlystages of cancer. By improving chemotherapy delivery to the tumor andinhibiting regrowth between treatment cycles, anti-VEGF agents mayalter the growth pattern of a tumor such that it is more susceptible toeradication. These concepts also suggest that anti-VEGF agents couldenhance the effectiveness of chemotherapy given conventionally or ina dose-dense fashion. As such, it is possible that the effectiveness ofchemotherapy could be maintained or improved, even at lower cumulativedoses, which may improve its tolerability. Additionally, the effectsof anti-VEGF agents on metronomic chemotherapy, which is reportedto have antiangiogenic properties on its own, warrant further evaluation.Preclinical data demonstrate that cytostatic angiogenesis inhibitorsare potent complementary agents to metronomic chemotherapy,producing sustained complete regressions in some models of humancancer. Dose-dense and metronomic chemotherapy have in common ashortened dosing interval and resultant increased and/or prolongedexposure of tumor cells to chemotherapy in vivo. Optimizing the use ofanti-VEGF agents in the clinic demands further investigation of themost appropriate way to combine them with chemotherapy, particularlyregimens designed to exploit known tumor growth patterns andthose designed to target the endothelial cells involved inneovascularization with multiple agents.

Granulocyte-macrophage colony-stimulating factor (GM-CSF,sargramostim [Leukine]) is a powerful cytokine that is able to stimulatethe generation of dendritic cells. Adjuvant treatment with continuous lowdoseGM-CSF has been shown to prolong survival of stage III/IV melanomapatients. Data on continuous low-dose GM-CSF therapy in tumorsother than prostate cancer are still lacking.

SAN ANTONIO-Updated results from the Intergroup Exemestane Study of 4,740 breast cancer patients show adjuvant therapy with the aromatase inhibitor exemestane (Aromasin) after 2 to 3 years of tamoxifen can cut risk of recurrence by

Carcinoma of the breast is the most common cancer in women in the United States and is second only to lung cancer as a cause of cancer death in women. The incidence of breast cancer has risen steadily over the past decade, with the most dramatic increase seen in smaller primary breast tumors, partly because widespread use of screening mammography permits earlier detection [1].

This section will examine several controversial or uncommon topics in breast cancer: use of dose-intensive therapy, estrogen replacement therapy, male breast cancer, and breast cancer in pregnancy. The section on dose-intensive therapy will trace the development and clinical rationale for the use of this therapy. For additional information, refer to the section on autologous bone marrow transplantation. Estrogen replacement therapy in patients previously treated for breast cancer is an area of active investigation and controversy.

Combined-modality positronemissiontomography (PET)–computed tomography (CT) isbecoming the imaging method ofchoice for an increasing number ofoncology indications. The goal of thispaper is to review the evidence-basedliterature justifying PET-CT fusion.The best evidence comes from prospectivestudies of integrated PETCTscans compared to other methodsof acquiring images, with histopathologicconfirmation of disease presenceor absence. Unfortunately, veryfew studies provide this kind of data.Retrospective studies with similarcomparisons can be used to provideevidence favoring the use of integratedPET-CT scans in specific clinicalsituations. Also, inferential conclusionscan be drawn from studies whereclinical rather than pathologic dataare used to establish disease presenceor absence.

SAN ANTONIO-Anastrozole (Arimidex) is the initial treatment of choice for postmenopausal women with hormone-receptor-positive (HR+) early breast cancer, Anthony Howell, MD, University of Manchester, UK, said at the 27th Annual San Antonio Breast Cancer Symposium (abstract 1). Final results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial showed the aromatase inhibitor to have superior efficacy and a better side effect profile than tamoxifen.

SAN ANTONIO-The bisphosphonate zoledronic acid (Zometa) effectively counteracts bone loss associated with combination endocrine treatment in premenopausal women with hormone-responsive breast cancer, Michael Gnant, MD, University of Vienna, said at the 27th Annual San Antonio Breast Cancer Symposium (abstract 6) on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).

SAN ANTONIO-For postmenopausal women with hormone-receptor-positive early-stage breast cancer, switching to anastrozole (Arimidex) after 2 years of tamoxifen is more effective than continuing on tamoxifen, according to Raimund Jakesz, MD, Vienna Medical School, Vienna, Austria. The conclusion arose out of analysis of combined results of two trials enrolling a total of 3,224 women: the Viennese ABCSG (Austrian Breast and Colorectal Cancer Study Group) Trial 8, and the German ARNO 95 Trial (by the German Adjuvant Breast Cancer Group).

ROCKVILLE, Maryland-Abraxane (paclitaxel protein-bound particles for injectable suspension, American Bioscience) has received Food and Drug Administration approval for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Previous therapy should include an anthracycline unless clinically contraindicated.

SAN ANTONIO-Sequential therapy with three cycles of fluorouracil, epirubicin (Ellence) 100 mg/m2, and cyclophosphamide (FEC-100) followed by three cycles of docetaxel (Taxotere) improved outcomes over six cycles of FEC alone, in node-positive breast cancer patients over the age of 50. Professor Henri Roche, Institut Claudius Regaud, Tou-louse, France, reported the results of the multicenter study from France and Belgium at the 27th Annual San Antonio Breast Cancer Symposium (abstract 27). While the study also included younger women, the significant improvements in disease-free and overall survival were limited to women aged 50 and older.

SAN ANTONIO-A randomized, multicenter trial from the United Kingdom has demonstrated what clinicians have instinctively felt: that sentinel node biopsy (SNB) is associated with less morbidity and better quality of life than standard axillary node surgery. Professor Robert E. Mansel, University of Cardiff, Wales, presented the results of the Axillary Lymphatic Mapping Against Nodal Axillary Clearance (ALMANAC) trial at the 27th Annual San Antonio Breast Cancer Symposium (abstract 18).

SAN ANTONIO-A 70-gene profile developed in Amsterdam to distinguish low-risk from high-risk women with node-negative breast cancer has been shown to be predictive for disease recurrence after surgery. Martine Piccart, MD, chair of the Breast International Group and head of the Medical Oncology Department, Institut Jules Bordet, Brussels, presented the results at the 27th Annual San Antonio Breast Cancer Symposium (abstract 38)

Dr Gundry comprehensivelydiscusses the role of breastmagnetic resonance imaging(MRI) in staging and screening breastcancer. I will emphasize and expandon some of the author’s key points.

Contrast-enhanced breast magnetic resonance imaging (MRI) is arelatively new but increasingly used modality for the detection of breastcancer. MRI has demonstrated utility in identifying additional tumorfoci and extent of disease in patients with known breast cancer. This isespecially useful with invasive lobular carcinoma, which is difficult toevaluate on mammography. MRI has been found to identify the primarytumor in 70% to 86% of cases of occult breast cancer. Contrastenhancedbreast MRI has shown some usefulness in the detection ofresidual cancer following surgery but is limited by postoperative changes.In patients who have undergone neoadjuvant chemotherapy, breast MRIis most accurate in those patients in whom there is little or no responseto chemotherapy. The use of contrast-enhanced breast MRI for breastcancer screening is controversial. It has only been used in a few smallstudies of high-risk patients. The limitations of breast MRI includeuptake in benign lesions and normal tissue, sensitivity for ductal carcinomain situ, cost, and availability. This paper will discuss the uses,benefits, and limitations of contrast-enhanced breast MRI in the stagingand screening of breast cancer.

In this excellent review of breastmagnetic resonance imaging (MRI),Gundry discusses the potential advantagesand disadvantages of magneticresonance in breast cancerscreening and management and givesrecommendations for how it shouldbe applied.

ATLANTA-A randomized trial finds that most women aged 50 or older who underwent breast-conserving surgery for early-stage breast cancer need radiation therapy (RT) in addition to tamoxifen to minimize the risk of a breast relapse. However, the data also suggest that selected women aged 60 or older may be able to safely skip radiation therapy. Lead author Anthony W. Fyles, MD, a radiation oncologist at the Princess Margaret Hospital, Toronto, Canada, presented findings of the trial at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (abstract 2). (For a full report, see N Engl J Med 351:963-970, 2004).

Several key areas must be considered in the diagnosis and managementof spinal cord compression. Because the outcome can be devastating,a diagnosis must be made early and treatment initiated promptly.Although any malignancy can metastasize to the spine, clinicians shouldbe aware that this occurs more commonly in certain diseases, ie, lungcancer, breast cancer, prostate cancer, and myeloma. The current algorithmfor early diagnosis of spinal cord compression involves neurologicassessment and magnetic resonance imaging of the entire spine.Treatment generally consists of intravenous dexamethasone followedby oral dosing. Depending on the extent of the metastases, symptomsmay also be managed with nonnarcotic pain medicines, anti-inflammatorymedications, and/or bisphosphonates, with local radiation administeredas needed. Surgery has often led to destabilization of the spine.

This study was designed to evaluate the cardiac safety of the combined treatment of HER2-positive metastaticbreast cancer patients with trastuzumab (Herceptin) plus epirubicin and cyclophosphamide (EC) incomparison with EC alone in HER2-negative metastatic breast cancer patients. Patients included those withmetastatic breast cancer without any prior anti-HER2 treatment, anthracycline therapy, or any other chemotherapyfor metastatic disease. This was a nonrandomized, prospective, dose-escalating, multicenter, openlabel,phase II study in Germany. A control group of 23 patients received EC 90/600 mg/m2 3-weekly for sixcycles (EC90 alone). A total of 26 HER2-positive patients were treated with trastuzumab, or H (2 mg/kg weeklyafter an initial loading dose of 4 mg/kg), and EC 60/600 mg/m2 3-weekly for six cycles (EC60+H); another 25HER2-positive patients received H and EC 90/600 mg/m2 3-weekly for six cycles. Asymptomatic reductions inleft ventricular ejection fraction (LVEF) of more than 10% points were detected in 12 patients (48%) treatedwith EC60 + H and in 14 patients (56%) treated with EC90 + H vs 6 patients (26%) in the EC90 alone cohort.LVEF decreases to < 50% occurred in one patient in the EC60+H cohort and in two patients in the EC90+Hcohort during the H monotherapy. No cardiac event occurred in the cohort with EC90 alone. The overallresponse rates for EC60+H and EC90+H were >60%, vs 26% for EC90 alone. The interim results of this studysuggest the cardiac safety of the combination of H with EC may be greater than that of H with AC (doxorubicin[Adriamycin]/cyclophosphamide); however, studies in larger numbers of patients are warranted. The combinationregimen revealed promising efficacy.

Adjuvant chemotherapy has been shown to be beneficial in patientswith breast cancer, and anthracycline-containing regimens are more effectivethan non–anthracycline-containing ones. The French AdjuvantStudy Group (FASG) compared FEC100 and FEC50 (fluorouracil[5-FU]/epirubicin [Ellence]/cyclophosphamide [Cytoxan, Neosar])in patients with node-positive breast cancer, with an end point of overallsurvival. After a median follow-up of 10 years, the benefit/risk ratio of theFEC100 regimen in patients with positive axillary nodes is strongly positive.Furthermore, a medicoeconomic study showed that the cost per yearof life saved was very low-approximately 1,000 euros.

The 6th University of Texas M. D. Anderson Cancer Center Investigators’Workshop was held on July 16–20, 2003, in Amelia Island, Florida.The purpose of these annual workshops has been to review the latest data onnew agents, with a particular emphasis on the broadly used agent irinotecan(Camptosar), and also novel regimens or agents.

Primary systemic therapy (ie, preoperative or neoadjuvant) increasesthe possibility for breast-conserving surgery in patients with primarybreast cancer. Patients with pathologic complete response to primarysystemic therapy have improved survival compared with those with persistenttumors. Several phase II trials have evaluated gemcitabine-containingdoublet or triplet regimens as primary systemic therapy for breastcancer, results of which have shown promising clinical and pathologicresponse rates with manageable toxicity. Results of a phase I/II studyof gemcitabine (Gemzar)/epirubicin (Ellence)/docetaxel (Taxotere), orGEDoc, with prophylactic filgrastim (Neupogen), as primary systemictherapy in 77 evaluable patients with primary breast cancer are reportedherein. Dose-limiting toxicities were grade 3 febrile neutropenia(n = 1) and grade 3 diarrhea (n = 2) at the fourth dose level ofGEDoc tested (gemcitabine at 800 mg/m2 days 1 and 8, epirubicin at90 mg/ m2 day 1, and docetaxel at 75 mg/m2 day 1). As assessed byultrasound, 92% of patients responded overall (22% complete response),and 79% of patients could undergo breast-conserving surgery. Thepathologic complete response rate in resected breast tissue was 26%.